Puma Biotechnology | PBYI - Gross Profit On Sales


Puma Biotechnology reported $20.32M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Daiichi Sankyo JPY 287.15B 152.68B Mar/2026
Exelixis USD 590.86M 18.68M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Moderna USD -566M 792M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026